AI Drug Discovery Expands
Aqemia and Sanofi Expand Drug Research Collaboration, Adding New Target and Payments
Anonymous
Aqemia has expanded its research collaboration with Sanofi, adding a new therapeutic target and an additional payment to a deal first struck in December 2023, according to National Post. The Paris-based AI drug company is now eligible to receive up to $140 million in total upfront and milestone payments across all programs in the partnership.
The expanded partnership brings together researchers across two continents. Aqemia teams in Paris and London are working alongside Sanofi scientists in Boston, Frankfurt, and Paris, Edmonton Sun reported. Sanofi is leading all wet lab research, development, and commercialization efforts.
AI Meets Physics to Invent New Drugs
Aqemia is not a typical drug company. It combines generative AI with quantum-inspired physics to design small molecule drugs. In simple terms, it uses advanced math and computing to predict which molecules could become medicines — before ever running a lab test, according to The Whig.
This approach is meant to speed up early drug discovery, which is normally slow and expensive. By finding the right molecules faster, the goal is to get better drug candidates to Sanofi's lab teams more quickly.
Deal Grows With New Target and Fresh Payment
The original collaboration launched in December 2023. Since then, Aqemia has added a new therapeutic target — meaning a new disease-related protein or pathway the partners will try to develop a drug against. That expansion also came with an additional payment, though the exact amount was not disclosed, per National Post.
The $140 million figure covers potential earnings across all programs in the deal. That total includes both upfront fees and milestone payments — money Aqemia receives when it hits key development goals.
Cross-Continent Teams Split Research and Commercialization
The partnership splits responsibilities clearly. Aqemia handles the AI-driven drug design side from its bases in Paris and London. Sanofi takes over from there, running wet lab experiments — real, physical tests on molecules — at its sites in Boston, Frankfurt, and Paris, according to Pembroke Observer.
Sanofi also owns the path to market. The global pharma giant is responsible for all development and commercialization once Aqemia's platform identifies strong drug candidates. That structure lets each partner focus on what it does best.
Sanofi Deepens Bet on AI-Driven Drug Discovery
This expansion signals growing confidence from Sanofi in AI-powered drug design. The company has been building partnerships with tech-forward biotech firms as part of a broader push to modernize how it finds new medicines, according to The Crag and Canyon.
For Aqemia, the deal validates its platform on a global stage. Landing and growing a multi-program collaboration with one of the world's largest pharmaceutical companies is a major step for a startup competing in an increasingly crowded AI drug discovery space.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
5
Articles
5
Reach
5
A
AnonymousAuthor